Adam W Carrico1, Judith Tedlie Moskowitz2. 1. Department of Community Health Systems, School of Nursing. 2. Osher Center for Integrative Medicine, University of California.
Abstract
OBJECTIVE: Revised Stress and Coping Theory proposes that positive affect serves adaptive functions, and its beneficial effects are heightened during stressful periods. This study examined the prospective relationship between positive affect and engagement in care during the 18 months after a HIV seropositive diagnosis. METHODS: The Coping, HIV, and Affect Interview (CHAI) cohort study enrolled 153 individuals who had recently received a HIV seropositive diagnosis. Using logistic and linear regression, baseline positive affect was examined as a predictor of linkage to HIV care, antiretroviral therapy (ART) persistence (i.e., starting ART and remaining on it during subsequent follow-up assessments), and mean log₁₀ HIV viral load over follow-up. RESULTS: After controlling for education, T-helper (CD4+) count, HIV viral load, and negative affect, higher baseline positive affect independently predicted increased odds of linkage to HIV care at 3 months postdiagnosis (adjusted OR [AOR] = 1.10; 95% CI = 1.01-1.21) and ART persistence over the 18-month follow-up period (AOR = 1.08; 95% CI = 1.01-1.16). Positive affect was not directly associated with lower mean HIV viral load over follow-up. However, one standard deviation higher positive affect indirectly predicted 6.7% lower HIV viral load via greater odds of ART persistence (βindirect = -0.18, p < .05). CONCLUSIONS: Greater positive affect predicts linkage to HIV care and ART persistence. ART persistence, in turn, is associated with lower HIV viral load. Clinical research is needed to examine whether interventions designed to enhance positive affect can boost the effectiveness of HIV treatment as prevention.
OBJECTIVE: Revised Stress and Coping Theory proposes that positive affect serves adaptive functions, and its beneficial effects are heightened during stressful periods. This study examined the prospective relationship between positive affect and engagement in care during the 18 months after a HIV seropositive diagnosis. METHODS: The Coping, HIV, and Affect Interview (CHAI) cohort study enrolled 153 individuals who had recently received a HIV seropositive diagnosis. Using logistic and linear regression, baseline positive affect was examined as a predictor of linkage to HIV care, antiretroviral therapy (ART) persistence (i.e., starting ART and remaining on it during subsequent follow-up assessments), and mean log₁₀ HIV viral load over follow-up. RESULTS: After controlling for education, T-helper (CD4+) count, HIV viral load, and negative affect, higher baseline positive affect independently predicted increased odds of linkage to HIV care at 3 months postdiagnosis (adjusted OR [AOR] = 1.10; 95% CI = 1.01-1.21) and ART persistence over the 18-month follow-up period (AOR = 1.08; 95% CI = 1.01-1.16). Positive affect was not directly associated with lower mean HIV viral load over follow-up. However, one standard deviation higher positive affect indirectly predicted 6.7% lower HIV viral load via greater odds of ART persistence (βindirect = -0.18, p < .05). CONCLUSIONS: Greater positive affect predicts linkage to HIV care and ART persistence. ART persistence, in turn, is associated with lower HIV viral load. Clinical research is needed to examine whether interventions designed to enhance positive affect can boost the effectiveness of HIV treatment as prevention.
Authors: Melanie A Thompson; Judith A Aberg; Jennifer F Hoy; Amalio Telenti; Constance Benson; Pedro Cahn; Joseph J Eron; Huldrych F Günthard; Scott M Hammer; Peter Reiss; Douglas D Richman; Giuliano Rizzardini; David L Thomas; Donna M Jacobsen; Paul A Volberding Journal: JAMA Date: 2012-07-25 Impact factor: 56.272
Authors: Edward M Gardner; Margaret P McLees; John F Steiner; Carlos Del Rio; William J Burman Journal: Clin Infect Dis Date: 2011-03-15 Impact factor: 9.079
Authors: Jason A Craw; Lytt I Gardner; Gary Marks; Richard C Rapp; Jeff Bosshart; Wayne A Duffus; Amber Rossman; Susan L Coughlin; DeAnn Gruber; Lauretta A Safford; Jon Overton; Karla Schmitt Journal: J Acquir Immune Defic Syndr Date: 2008-04-15 Impact factor: 3.731
Authors: Frederick M Hecht; Judith T Moskowitz; Patricia Moran; Elissa S Epel; Peter Bacchetti; Michael Acree; Margaret E Kemeny; Wendy Berry Mendes; Larissa G Duncan; Helen Weng; Jay A Levy; Steven G Deeks; Susan Folkman Journal: Brain Behav Immun Date: 2018-05-26 Impact factor: 7.217
Authors: Adam W Carrico; Walter Gόmez; Jennifer Jain; Steven Shoptaw; Michael V Discepola; David Olem; Justin Lagana-Jackson; Rick Andrews; Torsten B Neilands; Samantha E Dilworth; Jennifer L Evans; William J Woods; Judith T Moskowitz Journal: Drug Alcohol Depend Date: 2018-09-05 Impact factor: 4.492
Authors: Judith T Moskowitz; Adam W Carrico; Larissa G Duncan; Michael A Cohn; Elaine O Cheung; Abigail Batchelder; Lizet Martinez; Eisuke Segawa; Michael Acree; Susan Folkman Journal: J Consult Clin Psychol Date: 2017-03-23
Authors: Adam W Carrico; Walter Gómez; Michael D Siever; Michael V Discepola; Samantha E Dilworth; Judith T Moskowitz Journal: Arch Sex Behav Date: 2015-06-30
Authors: Shanell L McGoy; April C Pettit; Melissa Morrison; Leah R Alexander; Phadre Johnson; Brandon Williams; Darion Banister; Mary K Young; Carolyn Wester; Peter F Rebeiro Journal: Public Health Rep Date: 2018 Nov/Dec Impact factor: 2.792